A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
Letermovir Prophylaxis for Cytomegalovirus in Pediatric Hematopoietic Cell Transplantation
Sponsor: Children's Oncology Group
This PHASE3 trial investigates Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm and is currently actively recruiting participants. Children's Oncology Group leads this study, which shows 16 recorded versions since 2024 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
16 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE3
Status: Active Not Recruiting → Recruiting
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE3
-
Oct 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE3
▶ Show 11 earlier versions
-
Apr 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE3
-
Dec 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Apr 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
-
Dec 2023 — Apr 2024 [monthly]
Not Yet Recruiting PHASE3
-
Apr 2023 — Dec 2023 [monthly]
Not Yet Recruiting PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Children's Oncology Group
For direct contact, visit the study record on ClinicalTrials.gov .